Here is Why Growth Investors Should Buy BioMarin (BMRN) Now

Core Viewpoint - Investors are increasingly seeking growth stocks, particularly in the financial sector, to achieve above-average returns, but identifying such stocks can be challenging due to inherent volatility and risks [1] Group 1: Company Overview - BioMarin Pharmaceutical (BMRN) is currently highlighted as a recommended growth stock due to its favorable Growth Score and top Zacks Rank [2] - The company operates in the rare disease biopharmaceutical sector, which is characterized by strong growth potential [3] Group 2: Earnings Growth - BioMarin has a historical EPS growth rate of 36.8%, with projected EPS growth of 22.4% for the current year, significantly surpassing the industry average of 11.6% [4] - Double-digit earnings growth is a key indicator of strong prospects and potential stock price gains for growth investors [3] Group 3: Cash Flow Growth - The year-over-year cash flow growth for BioMarin stands at 23.3%, outperforming the industry average of -2.6% [5] - Over the past 3-5 years, the company's annualized cash flow growth rate has been 54.6%, compared to the industry average of 3.3% [6] Group 4: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for BioMarin, with the current-year earnings estimates increasing by 0.3% over the past month [7] - A strong correlation exists between earnings estimate revisions and near-term stock price movements, making this trend significant for investors [7] Group 5: Investment Positioning - BioMarin has achieved a Zacks Rank of 1 (Strong Buy) and a Growth Score of B, positioning it well for potential outperformance in the market [9] - The combination of strong earnings growth, cash flow growth, and positive earnings estimate revisions makes BioMarin an attractive option for growth investors [9]